Royal Philips (PHG) on Monday said it was expanding its partnership with Ibex Medical Analytics, further integrating Ibex's artificial intelligence tools for detecting and diagnosing prostate, breast, and gastric cancer into its IntelliSite Pathology scanners and image management systems.
Philips and Ibex began their partnership in 2021. Philips' IntelliSite Pathology platform received 510(k) clearance from the US Food and Drug Administration in July 2024, while Ibex received 510(k) clearance on Feb. 10 for its Prostate Detect, an in-vitro diagnostic device using AI to generate heatmaps identifying small and often-missed prostatic cancers.
Philips earlier this month also disclosed a collaboration with Amazon (AMZN) Web Services to offer cloud archival services for pathology labs, supporting efficient and secure storage and management of digital pathology data.
The company will be demonstrating its Philips IntelliSite Pathology Solution 6.0 at an industry conference now underway and running through Thursday in Boston, it said.
Price: 25.46, Change: -0.03, Percent Change: -0.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.